American International Group Inc vs Alcon AG — how do they compare? American International Group Inc trades at $77.4 (market cap $40.58B), while Alcon AG trades at $74.19 (market cap $35.19B). The key difference: American International Group Inc is the larger of the two by market cap, and American International Group Inc pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| AIG | ALC | |
|---|---|---|
Market Cap | $40.58B | $35.19B |
Sector | Financials | Health |
52-Week High | $86.59 | $90.12 |
52-Week Low | $71.89 | $62.02 |
Enterprise Value | $48.22B | $39.03B |
Dividend Yield | 2.58% | 0.49% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
Trailing returns across standard periods
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →